38

Objective. Data about the efficacy and safety of the latest COVID-19 treatments, nirmatrelvir/ritonavir (n/r) and sotrovimab, is scarce in solid organ transplant recipients in the Omicron era. This study aims to describe the outcome of kidney transplant recipients (KTRs) presenting Omicron infection according to their management: n/r, sotrovimab, or no specific treatment. Patients and methods. We conducted a monocentric, retrospective observational study, including KTRs diagnosed with Omicron infection between January and May 1, 2022 and compared their outcome (primary outcome defined as hospital admission for COVID-19 within a month after symptoms onset) according to early COVID-19 management. Results. Forty-five patients were included: 22 treated (12 n/r, 10 sotrovimab) and 23 with no specific treatment. The groups were statistically comparable. Two patients were admitted for COVID-19: one in each group, resulting in a non-different probability of the primary outcome at one month (p=0.9). Three patients presented with tacrolimus overdose, and two of these patients also presented with acute kidney injury. Conclusions. There was no difference in outcome depending on whether patients had early treatment with n/r, sotrovimab, or whether they had no specific treatment. Our study both highlights a decreased severity of Omicron COVID-19 in KTRs (probably related to vaccinal immunity and the decreased virulence of Omicron) and the potential severe adverse effects of n/r.